glp-1 prescriptions q1 2025 How Pharmacy Plans Are Managing Coverage in GLP-1 drugs: a game-changer for

The experiment For the trial, researchers recruited 48 adults with alcohol use disorder who werent actively seeking treatment

Schuurhuis, D

Each of these areas carries its own considerations related to dosing, precursor support, and patient selection

However, some patients may not achieve dramatic results, particularly if they miss doses or discontinue treatment prematurely

Efficacy and Safety of Oral Orforglipron in Patients With Type 2 Diabetes: A Multicentre, Randomised, Dose-Response, Phase 2 Study

A clinical trial published in 2022 found that an older GLP-1 drug called exenatide reduced drinking, but only among those who had both alcohol use disorder and obesity